Because increasingly, you have animals for the treatment of animals with cancer by the advance of medicine, veterinary gain valuable data on the development and treatment of cancer in humans by studies PET with new drugs. To arrange testing at the level of tumor cancer dog stock of medicines, the National Cancer Institute Comparative Oncology Trials Consortium (COTC). Faculty members at the University of Missouri’s program in Scott equipped veterinary oncology COTC in the first study.
“Spontaneous cancer dogs escorts offer a unique and largely unexplored opportunity for translational research for cancer imaging, the device and drug development,” said Carolyn Henry, professor and director of the program Scott Equipment veterinary oncology in the MU College of Veterinary Medicine. “End Report oncology MU has a long history of promoting cancer screening, treatment of both humans and dogs. COTC In the first study, we have a new Drug Delivery method, disrupts the flow of blood tumors but not surrounding tissue. The results have been effective, and we observe a decrease in tumor size in one of our patients. ” In the study, veterinary oncologist examines the effectiveness of a new method for the gene TNF-α to the tumor blood vessels. TNF-α protein in the body, of course, is that the anti-tumor effects. Given that TNF-α-protein toxicity can not be managed by blood. The researchers found that TNF-α gene-targeted on the tumor with a system based on bacteriophages. Bacteriophage is a virus that develops and seeks to infect the cells of tumor blood vessels. This specific system to reduce side effects, visit, if the protein is systemic. The comments, views on the determination of TNF-α for treatment of dogs and human patients, “said Henry.
“Rodent models not always show the complex relationship between exposure to drugs and the need for biological changes of tumor tissue in people,” said Henry. “This study provides unique information about the safety of these specific TNF-α therapy, which was not with rodent animal studies.”
The MU program Scott equipped veterinary oncology offers many opportunities for translational research. An ongoing project of cooperation with Valco Instruments, which specializes in manufacturing of various products for the biotechnology industry and IsoTherapeutics Group LLC, a developer of new diagnostics and therapies for the treatment of serious diseases for development of new technology by the administration of radiopharmaceuticals for the treatment of dog bone cancer. The new technique shows promise in the side effects of treatment. Canine osteosarcoma or bone cancer in dogs is very similar to bone cancer in children.
